Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Mar 15, 2018
- First patient dosed in Type 1 Spinal Muscular Atrophy Program - SOUTH PLAINFIELD, N.J. , March 15, 2018 /PRNewswire/ --   PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that the FIREFISH study of RG7916 in Type 1 spinal muscular atrophy (SMA) patients has transitioned into its pivotal
Additional Formats
Mar 06, 2018
- 2017 total revenues of $194M, a 135% increase vs. 2016 -
- Full year 2018 net product revenue guidance of $260M to $295M -
- Conference call at 4:30 p.m. ET -
Additional Formats
Mar 01, 2018
SOUTH PLAINFIELD, N.J. , March 1, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Cowen and Company 38 th Annual Health Care Conference , on Wednesday, March 14th at 8:00 a.m.
Additional Formats
Feb 28, 2018
SOUTH PLAINFIELD, N.J. , Feb. 28, 2018 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on February 26, 2018 it approved non-statutory stock options to purchase an aggregate of 96,750 shares of its common stock to sixteen new employees.
Additional Formats
Feb 21, 2018
SOUTH PLAINFIELD, N.J. , Feb. 21, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year end 2017 financial results and provide an update on the company's business and outlook on Tuesday,
Additional Formats
Feb 20, 2018
SOUTH PLAINFIELD, N.J. , Feb. 20, 2018 / PRNewswire/ --   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Office of New Drugs of the U.S. Food and Drug Administration has reiterated the FDA's prior position and denied PTC's appeal of the Complete Response Letter in relation to the
Additional Formats
Feb 13, 2018
- Grant Proposals from Nonprofit Patient Advocacy Organizations Due April 30, 2018
Additional Formats
Feb 09, 2018
SOUTH PLAINFIELD, N.J. , Feb. 9, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the upcoming 2018 RBC Capital Markets Global Healthcare Conference on Thursday, February 22nd at 2:35 pm ET .
Additional Formats
Jan 27, 2018
SOUTH PLAINFIELD, N.J. , Jan. 27, 2018 /PRNewswire/ --   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of early interim data from Part 1, the dose-finding portion of the FIREFISH study. FIREFISH is a two-part seamless, open-label, multi-center study to investigate the
Additional Formats
Jan 23, 2018
SOUTH PLAINFIELD, N.J. , Jan. 23, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that updates and preliminary data from ongoing clinical trials of RG7916, an oral survival motor neuron 2 (SMN2) splicing modifier in SMA patients will be presented at the International
Additional Formats